Report cover image

Gaucher Disease - Opportunity Assessment and Forecast

Publisher GlobalData
Published Dec 15, 2023
Length 59 Pages
SKU # GBDT18413944

Description

Gaucher Disease - Opportunity Assessment and Forecast


Summary

The prevalence of GD is increasing at a steady rate, in line with population growth in the 7MM, at an AGR of 0.39%.

Currently, the marketed treatment regimen for Type 1 GD and Type 3 GD is dominated by ERTs and SRTs (Cerezyme, VPRIV, Elelyso, Cerdelga, Zavesca).

There are several unmet needs in the GD landscape, including the lack of effective therapies for treating the neuropathic manifestations presented by Type 2 GD and Type 3 GD patients.

The GD R&D pipeline offers some innovative products, including gene therapy and venglustat malate, which is expected to be the first brain-penetrant SRT.

Steady market growth is expected throughout the forecast period as the GD population slowly increases and diagnostic approaches improve.

Key Highlights

Forecast includes 7MM: US, 5EU (France, Germany, Italy, Spain and the UK) and Israel.Forecasts cover 2022-2032.

Scope
  • Overview of GD, including epidemiology, symptoms, diagnosis, and disease management.
  • Annualized GD therapeutics market revenue in 7MM (US, 5EU and Israel), annual cost of therapy and treatment usage pattern in 2022 and forecast for 10 years to 2032.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the GD therapeutics market.
  • Pipeline analysis, comprehensive data assessing emerging trends and mechanisms of action under development for GD treatment. The most promising candidates in late-stage development are profiled.
  • Analysis of the current and future market competition in the 7MM GD therapeutics market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
Reasons to Buy
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the GD therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the GD therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

59 Pages
  • Executive Summary
    • Overview of Gaucher Disease
    • GD SWOT Analysis
    • Classification of GD
    • Diagnosed Prevalent Cases of GD, Men and Women, All Ages, 2022.32
    • Diagnosed Prevalent Cases of GD by Type, N, Men and Women, All Ages, 2022
    • Sources and Methodology: Diagnosed Prevalent Cases of GD
    • Sources and Methodology
    • Treatment Paradigm
    • Current Treatment Options
    • Product Profile: Enzyme Replacement Therapy (ERT)
    • Product Profile: Substrate Replacement Therapy (SRT)
    • Current Treatment Options: KOL Perspective
    • Unmet Needs in Gaucher Disease
    • Significant Lack of Neuropathic Therapies
    • Marketed Therapies Are Highly Expensive
    • Inconvenient Treatment Options
    • Earlier Diagnosis and Screening Is Required
    • Trends in Deal-Making in Gaucher Disease
    • Trends in Clinical Trial Design in Gaucher Disease
    • Gaucher Disease Pipeline Overview
    • Late-Stage Pipeline Agents for Gaucher Disease
    • Product Profile: Sanofi's Venglustat Malate
    • Product Profile: Sanofi's Eliglustat Tartrate
    • Product Profile: SZMC-Takeda's Ambroxol
    • Gaucher Disease: Clinical Trials (Phase II/III) Overview
    • Gaucher Disease Market Forecast
    • Gaucher Disease by Drug and Classes, 2022 and 2032
    • Gaucher Disease Market Forecast
    • Market Drivers and Barriers
    • Bibliography

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us